2026-10-06

340B Program Developments and Policy Updates

The 340B program is facing significant developments as HRSA has approved 10 pharmaceutical companies to participate in a revised rebate model pilot set to begin on January 1, 2027. Concurrently, the American Hospital Association (AHA) is advocating for a permanent ban on rebate models within the program, citing potential burdens on healthcare providers. Legal challenges continue to unfold, with updates in cases involving Mary Hitchcock Memorial Hospital against Eli Lilly, Henry Ford Hospital against CVS Health, and Florida Health Sciences Center against Eli Lilly. Johnson & Johnson has implemented new claims data requirements for 340B entities, further complicating compliance for covered entities. These developments reflect ongoing tensions between drug manufacturers and healthcare providers regarding the 340B program’s structure and its impact on patient care.

EXECUTIVE SUMMARY

HRSA approves 10 drugmakers for 340B rebate pilot.
HRSA has approved 10 pharmaceutical companies for a revised 340B rebate model pilot, starting January 1, 2027.

Source: Becker’s Hospital Review

AHA seeks permanent ban on 340B rebate models.
The American Hospital Association urges Congress to permanently ban rebate models in the 340B program, citing potential burdens.

Source: Becker’s Hospital Review

Mary Hitchcock Memorial Hospital v. Eli Lilly case update.
The court in D.N.H. received an amended complaint in the case against Eli Lilly regarding 340B pricing policies.

Source: CourtListener — D.N.H.

Henry Ford Hospital v. CVS Health Corporation update.
The E.D. Mich. court received a reply to a response to a motion in the case involving CVS Health’s 340B policies.

Source: CourtListener — E.D. Mich.

Florida Health Sciences Center v. Eli Lilly case update.
The M.D. Fla. court received a memorandum supporting a motion to dismiss in the case against Eli Lilly.

Source: CourtListener — M.D. Fla.

Johnson & Johnson imposes 340B claims data requirements.
J&J requires 340B entities to submit claims data within 45 days as a condition for discounts, amid increasing restrictions.

Source: HFMA

340B hospitals report less charity care spending.
A report finds 340B hospitals spend a smaller share of their budgets on charity care compared to non-340B hospitals.

Source: Becker’s Hospital Review

AHA files amicus brief in support of 340B hospital.
AHA filed a brief supporting Mary Hitchcock Memorial Hospital’s injunction request against Eli Lilly’s 340B policy.

Source: AHA

EXECUTIVE SUMMARY — KEY TAKEAWAYS

Most important 340B implication. The ongoing legal challenges and regulatory changes surrounding the 340B program have significant implications for covered entities. As pharmaceutical companies impose stricter claims data requirements and advocate for rebate models, hospitals and clinics may face increased administrative burdens and potential financial strain. The AHA’s push for a permanent ban on rebate models reflects concerns that these changes could undermine the program’s intent to provide affordable medications to vulnerable populations. The outcome of these legal cases and the implementation of new policies will likely influence how effectively covered entities can use the 340B program to support their mission of delivering charity care and maintaining financial viability in a challenging healthcare environment.

Emerging risks.

Hospitals may face cash flow challenges due to delayed rebates instead of upfront discounts.
Increased administrative burdens are likely with new claims data submission requirements.
Legal uncertainties persist as litigation over 340B policies continues.
Potential for reduced savings if rebate processes are inefficient or delayed.
Changes in drug pricing strategies by manufacturers could affect access and affordability.

Emerging opportunities.

Hospitals can use the rebate model to improve transparency in drug pricing.
The new CMS data repository provides a platform for better data management and compliance.
Engaging in the pilot could offer insights into optimizing drug procurement strategies.
Collaboration with manufacturers may improve negotiation power for better terms.
Participation in policy discussions could shape future 340B program developments.

Key actions for providers.

Hospitals should review and adjust financial strategies to accommodate rebate timing.
Prepare for mandatory data submissions by integrating systems with the CMS repository.
Monitor ongoing litigation and policy changes to anticipate operational impacts.
Engage with policymakers to advocate for favorable 340B program adjustments.
Train staff on new reporting and compliance requirements to ensure readiness.

TOP STORIES

AHA seeks permanent ban on 340B rebate models.

Becker’s Hospital Review · September 25, 2026

AHA urged Congress to ban rebate models in the 340B program permanently.
AHA warned of increased administrative and financial burdens on hospitals.
The SECURE 340B Act combines protections with new requirements.

FEDERAL POLICY & REGULATORY DEVELOPMENTS

AHA files amicus brief supporting Mary Hitchcock Memorial Hospital.

AHA · October 2, 2026

AHA filed a brief supporting the hospital’s injunction request against Eli Lilly.
The case challenges Eli Lilly’s 340B claims data policy.
AHA argues the policy threatens access to discounted drug prices.

340B PROGRAM DEVELOPMENTS

Johnson & Johnson adds 340B claims data requirements.

HFMA · October 5, 2026

J&J requires 340B entities to submit claims data within 45 days for discounts.
The policy reflects growing manufacturer restrictions in the 340B program.
Hospitals must comply to maintain access to discounted drugs.

340B hospitals spend less on charity care than peers.

Becker’s Hospital Review · September 28, 2026

340B hospitals spend 2.16% of expenses on charity care, less than non-340B hospitals.
The report shows disparities in charity care spending.
Critics argue 340B hospitals benefit financially without proportional patient benefits.

STATE DEVELOPMENTS

Texas: 340B Drug Discount Program Information Provided

Texas Department of State Health Services · October 4, 2026

The Texas Department of State Health Services has information about the 340B Drug Discount Program.
The program allows eligible entities to purchase outpatient drugs at reduced prices.
The initiative aims to help covered entities stretch scarce federal resources and provide more comprehensive services.

LITIGATION & ENFORCEMENT WATCH

Court	Matter	Date
D.N.H.	Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Amended Complaint. Case filed July 27, 2026. [source]	September 30, 2026
8th Cir.	Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source]	September 25, 2026
8th Cir.	Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source]	September 25, 2026
E.D. Mo.	AbbVie Inc. v. Hanaway — Memorandum and order: Accordingly, the Court grants Intervenors’ motion to intervene. see order for details. Case filed July 22, 2024. [source]	September 24, 2026
E.D. Mich.	Henry Ford Hospital v. CVS Health Corporation — Reply to Response to Motion. Case filed July 16, 2026. [source]	September 23, 2026
M.D. Fla.	Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Memorandum in support re Motion to Dismiss. Case filed July 2, 2026. [source]	September 23, 2026
8th Cir.	Novartis Pharmaceuticals Corp. v. Catherine L. Hanaway — Judge order: The petition for rehearing en banc is denied. The petition for panel rehearing is also denied. Case filed March 28, 2025. [source]	September 16, 2026
8th Cir.	AbbVie, Inc. v. Marty Jackley — Motion to hold briefing schedule in abeyance. Case filed August 11, 2026. [source]	September 15, 2026

MANUFACTURER WATCH

Manufacturer	Action	Date
Johnson & Johnson	Requires 340B claims data submission within 45 days for discounts. [source]	October 5, 2026

SOCIAL MEDIA & STAKEHOLDER SENTIMENT

I conducted a web search for recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, focusing on reactions, statements, op-eds, and advocacy positions from hospital and health-center groups, provider and patient advocates, drug manufacturers, PBMs, and policy commentators, including LinkedIn posts, Reddit discussions, and Substack/newsletter opinions.

340B Rebate Pilot Threatens Hospital Cash Flow in 2027

Healthcare Technology News · September 29, 2026

Main theme: Potential impact of the 340B rebate pilot on hospital cash flow starting in 2027.
Stakeholder sentiment: Hospital CEOs express concern that the shift to a rebate model could strain cash flow and affect staffing.
Potential implications: The change could tie up working capital, pressuring staffing and other expenditures supported by 340B savings.
Credibility: Healthcare Technology News is a specialized publication covering healthcare technology and policy.

WHAT TO WATCH NEXT

Implementation of the 340B rebate model pilot starts January 1, 2027. [source]
Potential legislative actions on the SECURE 340B Act in Congress. [source]
Court decisions in ongoing 340B litigation cases. [source]
Updates on Johnson & Johnson’s 340B claims data policy impact. [source]

End of briefing.

This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.

2026-10-06

Post information

Schedule Your 340B Assessment